These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24648760)

  • 1. Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.
    Areepium N; Panomvana D; Rungwanonchai P; Sathaporn S; Voravud N
    Breast Cancer (Dove Med Press); 2013; 5():73-8. PubMed ID: 24648760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of
    Charoenchokthavee W; Areepium N; Panomvana D; Sriuranpong V
    Breast Cancer (Dove Med Press); 2017; 9():249-256. PubMed ID: 28450788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
    Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
    Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.
    Blevins-Primeau AS; Sun D; Chen G; Sharma AK; Gallagher CJ; Amin S; Lazarus P
    Cancer Res; 2009 Mar; 69(5):1892-900. PubMed ID: 19244109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
    Sutiman N; Lim JSL; Muerdter TE; Singh O; Cheung YB; Ng RCH; Yap YS; Wong NS; Ang PCS; Dent R; Schroth W; Schwab M; Khor CC; Chowbay B
    Clin Pharmacokinet; 2016 Oct; 55(10):1239-1250. PubMed ID: 27098059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.
    Charoenchokthavee W; Panomvana D; Sriuranpong V; Areepium N
    Breast Cancer (Dove Med Press); 2016; 8():149-55. PubMed ID: 27540311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism.
    Koubek EJ; Buhrow SA; Safgren SL; Jia L; Goetz MP; Ames MM; Reid JM
    Drug Metab Dispos; 2023 Feb; 51(2):183-192. PubMed ID: 36351835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
    Romero-Lorca A; Novillo A; Gaibar M; Bandrés F; Fernández-Santander A
    PLoS One; 2015; 10(7):e0132269. PubMed ID: 26176234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen.
    Kanji CR; Nyabadza G; Nhachi C; Masimirembwa C
    J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
    Schroth W; Winter S; Mürdter T; Schaeffeler E; Eccles D; Eccles B; Chowbay B; Khor CC; Tfayli A; Zgheib NK; Eichelbaum M; Schwab M; Brauch H
    Front Pharmacol; 2017; 8():582. PubMed ID: 28955222
    [No Abstract]   [Full Text] [Related]  

  • 12. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
    Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
    J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer.
    Chiwambutsa SM; Ayeni O; Kapungu N; Kanji C; Thelingwani R; Chen WC; Mokone DH; O'Neil DS; Neugut AI; Jacobson JS; Ruff P; Cubasch H; Joffe M; Masimirembwa C
    Clin Pharmacol Ther; 2023 Jul; 114(1):127-136. PubMed ID: 37042388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
    Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
    Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.